The drug design AMP-001 involves pegylation of α-tocopheryl succinate (apoptogen) with a dipeptide linker valine-citrulline (VC) which is cleavable by tumor specific Cathepsin B enzyme giving rise to a biologically active final molecule (Scheme 1). Here, CTSB is linked to neoplasm.